The Research Innovation Group (RIG) manages the intellectual property portfolio and industry contracting activities for Saint Louis University.
RIG’s mission is to increase the adoption and dissemination of SLU research discoveries and intellectual properties and to leverage SLU research and innovation assets to benefit the community. Our goal is to become exceptional at technology transfer and industry engagement as well as a partner of choice for research and intellectual property commercialization.
RIG’s main office is located in CIC@4240 in the heart of the Cortex Innovation Community to better connect with industry and integrate SLU within the region’s innovation and entrepreneurship ecosystem. The Cortex Innovation Community was founded in 2002 through a collaboration among SLU, Washington University in Saint Louis, University of Missouri – St. Louis, BJC Healthcare, and the Missouri Botanical Garden. It is the Midwest’s premier innovation hub for research, development, and commercialization in biosciences and technology. Cortex anchors the St. Louis region’s growing innovation ecosystem for startups and established companies.
The Research Innovation Group at Saint Louis University strives to be fast, efficient, and helpful when serving community members. Let us know how we can best support you as you go pursue Truth. Please don't hesitate to contact us if you need further assistance.
The Research Innovation Group at Saint Louis University offers support and encouragement to student entrepreneurship, innovation, and research excellence in a variety of ways. All current students are very welcome to contact us if you have any questions.
MEDLaunch is a non-profit biomedical and entrepreneurship incubator partnering with Saint Louis University and other organizations in the Saint Louis area. The goal of MedLaunch is to improve the standard of healthcare through the engineering and design of creative solutions while also fostering a community of entrepreneurship and collaboration at Saint Louis University.
The Research Innovation Group at Saint Louis University is committed to leveraging our research and innovation assets for the benefit of our community. We strive to generate real impact in tackling social and scientific challenges facing our society through partnerships and programs.
The Research Innovation Group is committed to developing and implementing new approaches to technology transfer. It knows these will be needed to bring transformative discoveries resulting from university research more quickly and effectively to market. To this end, in September 2017, the Research Innovation Group brought together national leaders in technology transfer, regional innovators, entrepreneurs, business managers and advisors at the "Reinventing Research Commercialization Conference" to participate in this reinvention process.
The presentations from this conference are available below.
Saint Louis University strives to be a partner of choice for university research and intellectual property commercialization. Please contact us if you would like to discuss specific technologies or other opportunities to collaborate with us.
Please browse the categories below to learn more about our intellectual property portfolio and identify technologies that may be of interest to you.
|04-015||Method for detecting lysosomal storage diseases||Diagnostic|
|07-017||Novel products of myeloperoxidase useful in assessing cardiac health||Diagnostic|
|10-017||Biolayer interferometry measurement of biological targets||Diagnostic|
|10-024||Sickle confirm modified hemoglobin solubility test||Diagnostic|
|00-000||Diagnostic method for biomarkers of adverse coronary events||Diagnostic|
|05-009||Drug delivery from electroactive molecularly imprinted polymer||Drug Delivery|
|10-016||Passivated metal nanoparticles having an epoxide-based oligomer coating||Industrial Applications|
|10-023||Organelle bioelectrodes and methods of making||Industrial Applications|
|10-012||Methods and compositions for decomposition of biomass||Industrial Applications|
|04-001||Intramedullary nail device and method for repairing long bone||Medical Devices|
|05-016||Dental repair material||Medical Devices|
|07-023||Method and apparatus for sutureless injectable retinal detachment sponge implantation||Medical Devices|
|10-011||Method for controlling phase transformation temperature in metal alloy of a device||Medical Devices|
|10-015||Input device, a finger mouse for use in operating rooms||Medical Devices|
|10-02||Method and apparatus for delivery into the fetal trachea||Medical Devices|
|10-037||Locking screw device||Medical Devices|
|12-006||Foreign Body Location and Retrieval Device||Medical Devices|
|02-006||MPS IVa (Morquio A) mouse with point mutation and tolerant of human GALNS||Research Tools|
|05-008||Method of screening for a drug candidate that increases ATP release from RBCs stimulated via the Gs or Gi pathway||Research Tools|
|06-020||Compositions and methods for amplification and cloning of near full-length vial genome samples||Research Tools|
|07-004||Method for improving chemiluminescent signal||Research Tools|
|07-006||Screening tool for antiviral agents||Research Tools|
|10-008||Animal model for Parkinson's disease||Research Tools|
|10-025||Network threading approach for predicting a patient's response to hepatitis C virus therapy||Research Tools|
|11-004||Electronic research collaboration systems and methods||Research Tools|
|98-002||Mouse model for hemochromatosis wherein the HFE gene has been disrupted||Research Tools|
|98-008||C22: a conditionally immortalized mouse Clara cell line||Research Tools|
|98-013||Human NK 3.3 cell line||Research Tools|
|00-011||Factor IXa: Factor VIIIa interaction and methods therefore||Therapeutics|
|01-002||Proteins with an attached short peptide of acidic amino acids||Therapeutics|
|03-013||Method of manufacturing a stellate cell death factor||Therapeutics|
|03-019||Methods and compositions for vaccination||Therapeutics|
|06-002||Polypeptide fragment of constitutive coactivator of PPARgamma||Therapeutics|
|06-013||Chimeral polypeptide composition for cross-placenta delivery||Therapeutics|
|06-030||Methods and compositions for activated Protein C mutant with reduced anticoagulant properties||Therapeutics|
|06-047||Compositions and methods for treating immune system mediated diseases||Therapeutics|
|10-006||Method and composition for the management of cardiovascular disease with oligonucleotides||Therapeutics|
|10-007||Delivery of therapeutic agents to the bone||Therapeutics|
|10-010||Virus-expressing host costimulation molecules||Therapeutics|
|10-018||Peptides for inducing heterosubtypic influenza T cell responses||Therapeutics|
|10-021||Method of treating chronic pain||Therapeutics|
|10-032||Expression of anticoagulant thrombin mutants in Escherichia coli||Therapeutics|
|10-036||Prenatal enzyme replacement therapy||Therapeutics|
|10-038||Compositions and methods of treating disease by stimulating ATP release by red blood cells||Therapeutics|
|11-002||Use of adenosine A3 receptor agonists for treatment of neuropathic pain||Therapeutics|
|11-008||Compositions/therapy targeting neuromuscular junction||Therapeutics|
|11-015||Adenovirus E1A fragments for use in anti-cancer therapies||Therapeutics|
|11-017||Methods for treating inflammation||Therapeutics|
|11-027||Use of indomethacin-based drugs to treat Cornelia de Lange Syndrome||Therapeutics|
|11-031.1||Auto-activation of trypsin-like proteases||Therapeutics|
|Determination of immunogenic peptides in lysosomal enzymes and induction of oral tolerance||Therapeutics|
|12-013||Suppression of bone loss by introducing FOXP3+ CD8 T-cells||Therapeutics|
|12-014||Aminohydantoin Compounds as Antimalarial Agents||Therapeutics|
|13-023||Method for reducing incidence of fibrosis caused by peritoneal dialysis||Therapeutics|
|14-002||Antibody-based therapeutics for the treatment of diabetes complications||Therapeutics|
|14-011||Suppression of bone loss by introducing FoxP3+CD8 T-cells||Therapeutics|
|98-003||Temperature-sensitive and cold-adapted human parainfluenza virus type 2 (HPIV-2) and vaccines based on such virus||Therapeutics|
|99-018||Animal feed containing polypeptides||Therapeutics|